IHMT-MST1-39

IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42, 109, 286, 159 nM for MST1, MST2, MST3, MST4. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 can be used for the studies of type 1 diabetes (T1D) and type 2 diabetes (T2D) [1].

Product Specifications

CAS Number

[2414484-01-6]

UNSPSC

12352005

Target

AMPK; Apoptosis; Hippo (MST)

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ihmt-mst1-39.html

Purity

99.68

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1N(C)C2=CN=C(NC3=CC=C(S(=O)(N)=O)C=C3)N=C2N(C1C4=C(F)C=CC=C4F)C

Molecular Formula

C20H18F2N6O3S

Molecular Weight

460.46

References & Citations

[1]Wang J, et al. Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus. Signal Transduct Target Ther. 2023 Apr 5;8 (1) :143.